Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Armand

Showing results (31-40 of 240) with videos related to

Pageof 24
Sort By:
Bulletin Du Cancer|February 5, 1999
[Irinotecan: various administration schedules, study of drug combinations, phase I experience]V Boige, E Raymond, J P Armand
Bulletin Du Cancer|November 26, 1999
[Rapamycin and CCI-779]J Alexandre, E Raymond, J P Armand
Hematology/Oncology Clinics of North America|August 1, 1991
Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implicationsE Cvitkovic, M Bachouchi, J P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2004
Molecular targeting: targeting angiogenesis in solid tumorsJ-C Soria, J Fayette, J-P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
Targeting angiogenesis with oral agentsB Besse, J-P Armand, J-C Soria
Acta Crystallographica. Section C, Crystal Structure Communications|January 25, 2008
LiFe(MoO4)2, LiGa(MoO4)2 and Li3Ga(MoO4)3A van der Lee, M Beaurain, P Armand
Cancer Research|September 1, 1984
Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II)J P Macquet, S Cros, J P Armand
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trialsJ P Armand, L Seymour, T R Evans
Comptes Rendus Hebdomadaires Des Seances De L'Academie Des Sciences. Serie D: Sciences Naturelles|September 17, 1973
[Decrease of cellular immunity in hashish (marihuana) smokers]G Nahas, N Sucui-Foca, J P Armand
European Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?M Van Glabbeke, W Steward, J P Armand
Pageof 24

Showing results (31-40 of 240) with videos related to

Sort By:
Pageof 24
Bulletin Du Cancer|February 5, 1999
[Irinotecan: various administration schedules, study of drug combinations, phase I experience]V Boige, E Raymond, J P Armand
Bulletin Du Cancer|November 26, 1999
[Rapamycin and CCI-779]J Alexandre, E Raymond, J P Armand
Hematology/Oncology Clinics of North America|August 1, 1991
Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implicationsE Cvitkovic, M Bachouchi, J P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2004
Molecular targeting: targeting angiogenesis in solid tumorsJ-C Soria, J Fayette, J-P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
Targeting angiogenesis with oral agentsB Besse, J-P Armand, J-C Soria
Acta Crystallographica. Section C, Crystal Structure Communications|January 25, 2008
LiFe(MoO4)2, LiGa(MoO4)2 and Li3Ga(MoO4)3A van der Lee, M Beaurain, P Armand
Cancer Research|September 1, 1984
Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II)J P Macquet, S Cros, J P Armand
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trialsJ P Armand, L Seymour, T R Evans
Comptes Rendus Hebdomadaires Des Seances De L'Academie Des Sciences. Serie D: Sciences Naturelles|September 17, 1973
[Decrease of cellular immunity in hashish (marihuana) smokers]G Nahas, N Sucui-Foca, J P Armand
European Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?M Van Glabbeke, W Steward, J P Armand
Pageof 24